Quick Answer
ORAMED PHARMACEUTICALS INC. reported Total Assets of $230.86 million for the year ending 2025.
- ORAMED PHARMACEUTICALS INC. showed an increase of +48.7% in Total Assets from 2024 to 2025.
- This data is from ORAMED PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $3.90 million | Q1 2012: $3.14 million | Q2 2012: $2.47 million | Q4 2012: $6.82 million | Q1 2013: $5.96 million | Q2 2013: $4.85 million | Q4 2013: $8.01 million | Q1 2014: $23.71 million | Q2 2014: $22.50 million | Q4 2014: $24.56 million | Q1 2015: $22.98 million | Q2 2015: $22.13 million | Q4 2015: $23.88 million | Q1 2016: $38.37 million | Q2 2016: $36.31 million | Q4 2016: $44.93 million | Q1 2017: $41.84 million | Q2 2017: $39.79 million | Q4 2017: $41.54 million | Q1 2018: $38.25 million | Q2 2018: $34.66 million | Q4 2018: $43.59 million | Q1 2019: $41.81 million | Q2 2019: $37.43 million | Q4 2019: $31.14 million | Q1 2020: $29.88 million | Q2 2020: $46.16 million | Q4 2020: $40.97 million | Q1 2021: $61.66 million | Q2 2021: $80.49 million | Q3 2021: $128.00 million | Q4 2021: $182.45 million | Q1 2022: $172.22 million | Q2 2022: $162.29 million | Q3 2022: $164.44 million | Q1 2023: $159.78 million | Q2 2023: $156.31 million | Q3 2023: $230.89 million | Q1 2024: $203.65 million | Q2 2024: $184.22 million | Q3 2024: $165.08 million | Q1 2025: $147.54 million | Q2 2025: $161.68 million | Q3 2025: $220.49 million.
- Over the full 16 years of available data (2011 to 2025), ORAMED PHARMACEUTICALS INC.'s Total Assets has grown by 5,236.7%.
- Historical annual values: Fiscal year 2025: $230.86 million | Fiscal year 2024: $155.28 million | Fiscal year 2023: $220.55 million | Fiscal year 2022: $161.64 million | Fiscal year 2021: $177.82 million | Fiscal year 2021: $128.00 million | Fiscal year 2020: $44.63 million | Fiscal year 2019: $34.66 million | Fiscal year 2018: $47.40 million | Fiscal year 2017: $38.71 million | Fiscal year 2016: $42.83 million | Fiscal year 2015: $26.35 million | Fiscal year 2014: $21.80 million | Fiscal year 2013: $8.66 million | Fiscal year 2012: $5.29 million | Fiscal year 2011: $4.33 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: